is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The pharmaceutical product lifecycle is a complex process with several touchpoints that needs to balance efficient deployment of essential medicines to patients with strict safety compliance, in one of the world’s most heavily regulated sectors.
The global emergency that is COVID-19 has exerted even more pressure on pharmaceutical supply chains, as the industry races not only to develop potential vaccines and therapies for the virus in record time but also to scale up manufacturing to make these treatments available to a global population.
Each year we unite more than 100,000 pharmaceutical professionals through exhibitions, conferences and online communities. Global Pharma Insights provides information to aid effective decision making in all the following sectors and more:
• Drug development (pre-clinical and clinical) • API sourcing and procurement • Drug manufacturing and outsourcing • Pharmaceutical packaging and drug delivery • Pharmaceutical distribution • Cell and gene therapies • Cell and gene therapies • Artificial intelligence and machine learning
CPhI Korea is closely monitoring developments concerning the COVID-19. The health and safety of both our customers and colleagues is always our top priority. As such, we are following all safety advice and precautions as recommended by local Departments of Health, as well as the World Health Organization (WHO).
Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
This report covers the areas within the life sciences where Korea is gathering an increasingly strong international reputation, highlighting the country’s progress in R&D and clinical trials, its thriving biotech ecosystem, and its growing footprint in the exciting field of regenerative medicine..
Industry forecast for the Korean pharmaceutical market. Source: BMI Research. Strong demand: Korea’s pharmaceutical market is set to expand at a steady pace over the coming years. An amicable market: As indicated by universal healthcare coverage and high purchasing power. 2.8%: 10-year compound annual growth rate (CAGR). Medical launche:; A primary market alongside Australia, Canada, the US, Japan and Western Europe.
1989: Universal health coverage for South Korean population. 1991: Korea joins the World Health Organization Programme for International Drug Monitoring . 1996: Korea Food and Drug Safety and its six regional offices are established. 1998: The government agency is raised to the status of administration: Korea Food & Drug Administration. Learn more!
Key Statistics: 4th largest pharmaceutical market in the Asia Pacific, Ranked 1st in 2018 Bloomberg Innovation Index, Home to over 40 pharmaceutical multinationals, Global biotech and medical industry hub by 2020. Learn more!
What does 2019 have in store for Pharma? We asked industry Thought Leaders to name one disruptive trend or technology that will have a significant impact on the market in the year ahead. Will pricing pressure lead to a shift in budget management? Is this the year for biosimilar approvals? Will we see continued M&A activity in the sector?
Traditional Chinese medicine (TCM) has been used within China for thousands of years. Comprising practices such as herbal pharmacology, acupuncture and massage, it is grounded in the belief that the body is a system of balance, with a vital energy (chi) circulating around it in channels. When there are imbalances in the body, disease ensues.
This surge in international companies wanting to partner in Korea reflects a flourishing South Korean pharma economy, which, in recent years, has become the 3rd largest pharma region in Asia, with a forecasted growth from $18.6 billion in 2016 to $20.4 billion in 2020.
IQVIA and CPhI are pleased to bring you our special Market Prognosis report sharing our view of the future of the South Korean pharma market. Both CPhI and IQVIA consider that such information is key for the growth and development of the pharma industry and believe that this report will provide valuable insight as you look to develop your business in South Korea.